“showed a trend”

Both the A2620 and the Hyrax expanders showed a trend in the developed force that increased up to about 18–20 activations, after which a “plateau” was reached, while the Palatal Split Screw succeeded in increasing the force up to 24 activations (Figure 4 ).

Extending the results of a previous study that showed a trend toward a correlation of circulating irisin with BMI in subjects with a BMI range from 20 to 48 kg/m 2 ( 6 ), we previously reported a positive correlation of plasma irisin levels with BMI over a very broad spectrum of body weights with BMIs ranging from 8 to 85 kg/m 2 as well as positive associations with fat mass (FM), fat-free mass (FFM), and body cell mass (BCM) ( 11 ).

Among them, the TNT and IDEAL trials showed a trend toward an increase in new-onset diabetes for the atorvastatin 80 mg group compared with atorvastatin 10 mg (HR, 1.10; 95% CI, 0.94 to 1.29) or simvastatin 20 mg (HR, 1.19; 95% CI, 0.98 to 1.43).

In addition, average% PSA changes in the responder group showed a trend of PSA plateau.

Patients in more severe symptom groups showed a trend towards a higher number of comorbidities (Table 1 ) and were more likely to be on a current MM regimen (Table 2 ).

Ill participants as a group showed a trend of reduction of sweat volume on foot more than that of proximal sites by QSART compared to Controls, suggesting the possibility of a length-dependent small fiber dysfunction.

Although this study was not powered to compare between rituximab doses, exploratory results showed a trend of more radiological protection with the higher dose, which is clinically relevant in RA patients with early disease.

There is no enough evidence to support the routine use of diuretics for prevention or treatment of congestive heart failure in HS-PDA, and a systematic review of the coadministration of furosemide in indomethacin-treated neonates showed a trend toward failure of ductal closure in furosemide-treated patients because furosemide increases prostaglandins production and could potentially decrease the ductal response to indomethacin [ 119 ].

Analysing the site of bleeding, rivaroxaban showed a trend towards increased risk of major upper gastrointestinal bleeding and major lower gastrointestinal bleeding, while dabigatran increased the risk of major lower gastrointestinal bleeding ( Figure 7 ).

In other words, plant and butterfly communities at the upper limit of the tree line showed a trend for an average downhill shift of 12 m and 40 m, respectively, within the eight years of the study.

The secondary outcome, the PP, showed a trend for the sum of the drug effect and the placebo effect (δ+μ) (mean PP 35.2 (95% CI, 27.0–43.3)) being larger than the total treatment effect (γ) (mean PP 30.0 (95% CI, 25.0–35.1)) (P = 0.065, paired t-test).

However, individuals in Cronulla (U, D, TL from Palm Beach) and those transplanted to Long Bay showed a trend for more bleaching.

In the case reported here, diagnosis was firstly established by clinical features and by culture, but later by the therapeutic response to the itraconazole which was remarkable, because in vitro studies Fusarium performed by other authors have showed a trend towards resistance to azole antifungals [20] .

Fluorescence optical measurements on paraffin sections of 38 donors (aged 2 to 90 years; 19 whites, 16 American blacks) showed a trend of decreasing content with aging in both RPE and choroidal melanocytes [ 10 ].

Cross‐Sectional Associations of Circulating n‐3 ALA and n‐6 PUFA With CVD Risk Factors Circulating ALA was positively associated with plasma triglycerides, inversely associated with LDL‐C, and CRP, and showed a trend toward higher plasma HDL‐C ( P trend =0.08; Table 4 ) and higher sTNF‐R1 ( P trend =0.08).

Conduit vessel endothelial‐dependent vasorelaxation (brachial artery FMD) showed a trend to improve during pioglitazone treatment but this did not reach statistical significance, nor did microvascular endothelial function (RHI) significantly improve during treatment with active drug.

In contrast, the only STAT protein that showed a trend increase in phosphorylation after the second period of incubation was STAT3, suggesting a possible role of JAK1-STAT3 pathway in the proliferation rebound observed after withdrawal of the drug.

Aerial, land, and ship-based surveys of pup and non-pup Steller sea lion counts conducted during the time frame of this study showed a trend of slowing population decline in some regions of the western DPS.

Moreover, maximum NDII showed a trend opposite to precipitation in this year.

Lung function indices showed a trend of benefit for active treatment compared with the placebo group for those variables that reflect respiratory effort (forced vital capacity and forced expiratory volume in one second).

The study showed a trend towards a decrease in exacerbations and a significant improvement in lung function in omalizumab-treated patients, as compared with the placebo group.

Higher BMI showed a trend towards association with risk of IP (adjusted HR 1.45 (0.95 to 2.21) for BMI ≥ 30 vs normal weight) and RA, but not seropositive IP (HR 1.05 (0.61 to 1.79), age- and gender-adjusted).

Several NSCLC trials and meta-analysis have compared sequential and concomitant combinations directly, almost all of which showed a trend in favor of concomitant radiochemotherapy.[ 5 , 6 ] However, some authors still believe that more evidence is required to prove the superiority of concurrent chemoradiation due to heterogeneity of the included trials in the meta-analysis, low patient numbers and lack of statistical power.[ 7 ] Most of the data supporting this observation comes from the developed world and rarely have good-quality clinical trials been carried out in developing countries.

At steady state, empagliflozin concentration–time profiles showed a trend similar to single dose profiles on day 1 (Fig. 1 ) [note, 2 patients (1 each from the 10 mg and 100 mg dose groups on day 9) were excluded due to incomplete data or low exposure].

100 mg/day) showed a trend towards improved efficacy in subgroups of patients (APACHE II score >20, neutropenia) and might be used in selected patients [ 19 , 36 , 128 ].